Sudeep Pharma Ltd Q1 FY27 Earnings Analysis

- Pharma Food Nutrition (PFN) segment expected to grow faster than FY26 (which was ~10% growth), with continued momentum in FY27 and FY28. - Specialty Ingredients segment projected to maintain similar strong growth as past 2-3 years, supported by growing demand in infant nutrition, medical nutrition, sports nutrition, and dietary supplements. - New bisglycinate product category poised for significant scale-up from FY27, with higher margin contributions expected starting FY28; global market size around $1 billion with 40-50% in North America. - Battery materials business ramping up with phase 1 capacity targeting 25,000 MT, progressing toward 100,000 MT full capacity; projected revenues around INR1,600-1,800 crores at peak. - Overall, excluding battery materials, the business can scale to INR1000-1200 crores revenue without additional capex. - Capacity utilization currently moderate (65-70% pharma, 35-40% specialty), expected to improve with new greenfield projects enabling higher volumes and margin expansion.

- FY27 expected to mark an inflection point with continued momentum in both pharma food nutrition and specialty ingredients verticals. - Pharma food nutrition segment expected to grow at a faster rate than FY26's 10%; specialty ingredients to maintain steady growth. - Margins are projected to improve back to historical levels of around 37-38% EBITDA by FY27, aided by earlier investments starting to contribute positively. - Capacity expansions planned to allow pharma food nutrition business to scale to INR 1000-1200 crores without incremental capex. - Battery materials business targeted for 100,000 metric tons capacity by 2027, with potential revenue of INR1,600-1,800 crores at peak utilization. - Overall, margin and revenue growth expected due to new product introductions, higher-value molecules, expanded manufacturing infrastructure, and product mix shift towards specialty and high-performance chemicals. - EPS is expected to benefit correspondingly from these margin improvements and revenue growth drivers in FY27 and beyond.

- Battery Materials Project at Dahej: - Phase 1 capacity of 25,000 metric tons per year, commissioning targeted by April 2027. - Total capex for full 100,000 tons capacity expected around INR 600 crores. - Current capex higher due to land acquisition, infrastructure for Phase 2 included. - Greenfield Manufacturing Project: - Focused on pharma, food, and nutrition verticals. - Commissioned recently; customer qualification process ongoing (6-12 months). - Expected to enhance capabilities in high-value molecules like glycinate, gluconate. - FY27 Capex Outlook: - Major greenfield expansion nearing completion. - Approximate capex of INR 10 crores to complete the project. - Maintenance capex around INR 15 crores expected. - Other Investments: - Significant spend in FY26 on greenfield and SAM land purchase (INR 127 crores total). - Ongoing investments in commercial presence, technical teams, warehousing, and supply chain in Europe and North America to support growth.

- There is no explicit mention of any current or immediate future fundraising through debt or equity in the transcript. - FY26 ended with a conservative net debt position of INR 33.6 crores and a low net debt-to-equity ratio of 0.04x, indicating comfortable leverage. - Capex plans for FY27 include around INR 10 crores to complete the greenfield project and INR 15 crores of maintenance capex in the core business. - The battery materials project has a total planned capex of approximately INR 600 crores for 100,000 metric tons capacity, but no mention of financing plans. - Overall, the company appears focused on capacity expansion funded through internal accruals and disciplined execution rather than new debt or equity issuance at present.

- Sudeep Pharma has strong customer engagement with 42 customers across cathode, cell, EV, and ESS ecosystems globally. - Of these, 22 customers are at lab validation stage, 14 at pilot-scale evaluation, and 6 have completed commercial validation with active off-take discussions. - Recently received initial commercial purchase orders including approximately 700 metric tons over the last month, indicating growing demand. - For battery materials, 700 metric tons of orders have been received, with commercial production capacity ramping up. - Specialty ingredients have a healthy order book with visibility from key global customers, including approvals from top bakery and infant nutrition companies. - The company is confident of maintaining growth momentum in specialty ingredients and pharma food nutrition segments in FY27 and FY28.